2.0 d0e807fd-a44a-48e5-891f-6fd1ad995349 *AOS_Lung_L central SBRT 50Gy 5fx v1 Thorax Lung Left *AOS_Lung_L central SBRT 50Gy 5fx AOS sample template - to be copied, reviewed, modified as deemed appropriate, and approved by site physicist Summary: 5 fx left ultra-central lung SBRT to 50 Gy Reference: RTOG 0813 "Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients".Version 1.0 v 1.5 Created: 2/3/25 (BSM SEG) Last updated: 4/18/25 (PHH) - adjusted influencer P levels and sub-P ordering, corrected OAR label (Bronchus_Main) ********************************************************************* Rx: "Patients will receive 5 fractions of radiation, on an every 2-day basis i.e., 2-3 treatments per week, so that the SBRT schedule is completed within 1.5-2 weeks. There should be a minimum of 40 hours between treatments." - RTOG 0813 PTV margin: "An additional 0.5 cm in the axial plane and 1.0 cm in the longitudinal plane (craniocaudal) will be added to the GTV to constitute the PTV for centers acquiring image datasets using helical scanning. The methodology employed for centers incorporating 4DCT image datasets into target definition and treatment planning must first be approved through the process described in Section 5.3.2. Institutions using 4DCT must provide on a per-person basis the following information: method of image acquisition, utilization of the 4DCT image datasets, and the expansion margin to define the PTV. In addition, for each plan the target motion measured from 4DCT must be submitted." - RTOG 0813 Normalization: "Normalization: The treatment plan should be normalized such that 100% corresponds to the center of mass of the PTV (COMPTV). This point will typically also correspond (but is the center of mass of the PTV" - RTOG 0813 Prescription Isodose Surface Coverage: "The prescription isodose surface will be chosen such that 95% of the target volume (PTV) is conformally covered by the prescription isodose surface and 99% of the target volume (PTV) recieves a minimum of 90% of the prescription dose." - RTOG 0813 Dose Heterogeneity and Conformality: See Section 6.4.2.3 of RTOG 0813 page 16. OAR Constraints and contouring: See Table 2, Section 6.5.1 and Section 6.5.2 of RTOG 0813 page 18. Structures have been named according to TG 263. 5018 FMA 3.2 Bones 4289396157 Bones 7088 FMA 3.2 Heart 4294957055 Heart 7131 FMA 3.2 Esophagus 4289068874 Esophagus 7309 FMA 3.2 Lung right 4278190284 Lung_R 7310 FMA 3.2 Lung left 4294967040 Lung_L 45245 FMA 3.2 Brachial plexus left 4294934720 BrachialPlex_L 45244 FMA 3.2 Brachial plexus right 4286578943 BrachialPlex_R T-D3219 SRT Great vessels of the heart 4291454208 GreatVes 7394 FMA 3.2 Trachea 4278190335 Trachea 264793 FMA 3.2 Set of left ribs 4278223103 Ribs_L 264792 FMA 3.2 Set of right ribs 4291624908 Ribs_R 7163 FMA 3.2 Skin 4286644096 Skin Body BODY 99VMS_STRUCTCODE 1.0 Body plus other external items 5 0 ]]> 7148 FMA 3.2 Stomach 4294934720 Stomach 9869 FMA 3.2 Pericardium 4294901888 Pericardium 7197 FMA 3.2 Liver 4278206464 Liver 7405 FMA 3.2 Main bronchus 4289986559 Bronchus_Main 68877 FMA 3.2 Both lungs 4294934528 Lungs 7647 FMA 3.2 Spinal cord 4278255615 SpinalCord GTVp 99VMS_STRUCTCODE 1.0 Primary gross tumor volume 4285868492 GTV primary ITV 99VMS_STRUCTCODE 1.0 Internal target volume 4294934528 ITV R-429EC SRT Planning target volume 4294901760 PTV Target2 ITV 99VMS_STRUCTCODE 1.0 Internal target volume 3.0000000000000004 3.0000000000000004 10 3.0000000000000004 3.0000000000000004 10 Body BODY 99VMS_STRUCTCODE 1.0 Body plus other external items -2 ]]> HealthyTissue 99VMS_STRUCTCODE 1.0 Generic healthy tissue 4280929353 Lungs-GTV OAR5 7310 FMA 3.2 Lung left OAR4 7309 FMA 3.2 Lung right OAR16 7405 FMA 3.2 Main bronchus Target1 GTVp 99VMS_STRUCTCODE 1.0 Primary gross tumor volume OAR9 7394 FMA 3.2 Trachea ]]> Target3 10 DoseVolume ShouldBeMoreOrEqual 95 Relative 100 Relative 1 1 DoseVolume ShouldBeMoreOrEqual 90 Relative 99 Relative 3 1 OAR2 DoseVolume ShouldBeLess 15 Absolute 32 Absolute 3 3 OAR2 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 52.5 Absolute 3 10 OAR2 MeanDose OAR3 DoseVolume ShouldBeLess 5 Absolute 27.5 Absolute 3 7 OAR3 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 52.5 Absolute 3 11 OAR3 MeanDose OAR6 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 32 Absolute 3 13 OAR7 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 32 Absolute 4 1 OAR8 DoseVolume ShouldBeLess 10 Absolute 47 Absolute 2 1 OAR8 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 52.5 Absolute 3 5 OAR9 DoseVolume ShouldBeLess 4 Absolute 18 Absolute 3 6 OAR9 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 52.5 Absolute 3 9 OAR10 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 52.5 Absolute 4 2 OAR11 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 52.5 Absolute 4 3 OAR12 DoseVolume ShouldBeLess 10 Absolute 30 Absolute 4 4 OAR12 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 32 Absolute 4 5 OAR13 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 25 Absolute 3 12 OAR13 MeanDose OAR14 DoseVolume ShouldBeLess 15 Absolute 32 Absolute 3 4 OAR14 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 52.5 Absolute 3 14 OAR14 MeanDose OAR15 DoseVolume ShouldBeLessOrEqual 700 Absolute 17 Absolute 3 15 OAR15 MeanDose OAR16 DoseVolume ShouldBeLess 4 Absolute 18 Absolute 3 2 OAR16 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 52.5 Absolute 3 8 OAR18 DoseVolume ShouldBeLessOrEqual 0.25 Absolute 22.5 Absolute 1 2 OAR18 DoseVolume ShouldBeLessOrEqual 0.5 Absolute 13.5 Absolute 2 2 OAR18 DoseVolume ShouldBeLessOrEqual 0.03 Absolute 30 Absolute 2 3 ControlRegion1 DoseVolume ShouldBeLess 1500 Absolute 12.5 Absolute 2 4 ControlRegion1 DoseVolume ShouldBeLess 1000 Absolute 13.5 Absolute 2 5 ControlRegion1 MeanDose OAR5 MeanDose OAR4 MeanDose NoNormalization 1 None 1 None 1 None 1 None 1 None